JP6554493B2 - 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス - Google Patents

可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス Download PDF

Info

Publication number
JP6554493B2
JP6554493B2 JP2016575085A JP2016575085A JP6554493B2 JP 6554493 B2 JP6554493 B2 JP 6554493B2 JP 2016575085 A JP2016575085 A JP 2016575085A JP 2016575085 A JP2016575085 A JP 2016575085A JP 6554493 B2 JP6554493 B2 JP 6554493B2
Authority
JP
Japan
Prior art keywords
poly
copolymer
acid
nanoparticles
polar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016575085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520567A5 (cg-RX-API-DMAC7.html
JP2017520567A (ja
Inventor
ロバート エフ. パージェルス,
ロバート エフ. パージェルス,
ロバート ケー. プルドーム,
ロバート ケー. プルドーム,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of JP2017520567A publication Critical patent/JP2017520567A/ja
Publication of JP2017520567A5 publication Critical patent/JP2017520567A5/ja
Application granted granted Critical
Publication of JP6554493B2 publication Critical patent/JP6554493B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0097—Dye preparations of special physical nature; Tablets, films, extrusion, microcapsules, sheets, pads, bags with dyes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016575085A 2014-06-24 2015-06-16 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス Active JP6554493B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016363P 2014-06-24 2014-06-24
US62/016,363 2014-06-24
PCT/US2015/036060 WO2015200054A2 (en) 2014-06-24 2015-06-16 Process for encapsulating soluble biologics, therapeutics, and imaging agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019126795A Division JP7019195B2 (ja) 2014-06-24 2019-07-08 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス

Publications (3)

Publication Number Publication Date
JP2017520567A JP2017520567A (ja) 2017-07-27
JP2017520567A5 JP2017520567A5 (cg-RX-API-DMAC7.html) 2019-01-24
JP6554493B2 true JP6554493B2 (ja) 2019-07-31

Family

ID=54938922

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016575085A Active JP6554493B2 (ja) 2014-06-24 2015-06-16 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス
JP2019126795A Active JP7019195B2 (ja) 2014-06-24 2019-07-08 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019126795A Active JP7019195B2 (ja) 2014-06-24 2019-07-08 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス

Country Status (5)

Country Link
US (4) US10231937B2 (cg-RX-API-DMAC7.html)
EP (2) EP4299058A3 (cg-RX-API-DMAC7.html)
JP (2) JP6554493B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015280417B2 (cg-RX-API-DMAC7.html)
WO (1) WO2015200054A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200054A2 (en) 2014-06-24 2015-12-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2017112828A1 (en) * 2015-12-22 2017-06-29 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2019050969A1 (en) * 2017-09-06 2019-03-14 Prud'homme, Robert, K. FORMULATIONS OF DIHYDROMYRICETIN NANOPARTICLES
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
JP2021501753A (ja) 2017-11-03 2021-01-21 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティThe Trustees Of Princeton University 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿
US11214672B2 (en) 2018-01-19 2022-01-04 The Trustees Of Princeton University Hybrid polymer-inorganic nanocolloids and methods of making them
EP3517879B1 (en) 2018-01-25 2020-09-09 Valeo Vyminiky Tepla, s.r.o. Feeding plate for heat exchanger
WO2019227169A1 (en) * 2018-05-31 2019-12-05 The University Of Queensland Core-shell polymer nanoparticle
CN108938593B (zh) * 2018-07-16 2021-06-08 中山大学 一种脂质包裹固体药物纳米颗粒的制备方法
WO2020018890A1 (en) * 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US20220211637A1 (en) * 2019-05-09 2022-07-07 The Trustees Of Princeton University Random copolymer stabilized nanoparticles encapsulating soluble hydrophilic compounds
US12296045B2 (en) 2019-05-24 2025-05-13 President And Fellows Of Harvard College Copolymers for stabilizing emulsions and/or forming interfacial films, and methods thereof
MX2021015457A (es) 2019-06-14 2022-04-06 Univ Princeton Formulaciones de dihidromiricetina y un permeabilizante.
WO2021046078A1 (en) 2019-09-04 2021-03-11 The Trustees Of Princeton University Comb polymer and block copolymer stabilized nanoparticles encapsulating nucleic acids and other soluble hydrophilic compounds
US12486245B2 (en) 2019-10-21 2025-12-02 The Trustees Of Princeton University Sequential multi-step flash nanoprecipitation for the formation of nanoparticles with high core loadings
US20210169818A1 (en) * 2019-11-15 2021-06-10 Xuefei BAI Transdermal Delivery System
US11925705B2 (en) * 2021-09-16 2024-03-12 The Curators Of The University Of Missouri Method for continuous fabrication of multi-functional nanogels
WO2023122331A2 (en) * 2021-12-23 2023-06-29 Optimeos Life Sciences, Inc. Nanoparticles and methods of production for the encapsulation of nucleic acids
WO2025199353A1 (en) * 2024-03-21 2025-09-25 Purdue Research Foundation Nanoparticulate formulations and foliar administration thereof in the treatment and prevention of citrus greening disease

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1690760A (en) 1927-01-05 1928-11-06 Abbott Lab Enteric coated capsule
US4342653A (en) 1979-02-15 1982-08-03 American Cyanamid Company Process for the flocculation of suspended solids
US4382982A (en) * 1979-12-07 1983-05-10 Ici Australia Limited Process for protecting magnetic particles with chromium oxide
US5366734A (en) 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
US4678516A (en) 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4695464A (en) 1984-10-09 1987-09-22 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4888238A (en) * 1987-09-16 1989-12-19 James River Corporation Superabsorbent coated fibers and method for their preparation
US4999417A (en) 1989-03-30 1991-03-12 Nova Pharmaceutical Corporation Biodegradable polymer compositions
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
AU3649697A (en) 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5851579A (en) 1996-10-28 1998-12-22 Eastman Chemical Company Aqueous enteric coating compositions
US6730322B1 (en) 1998-04-30 2004-05-04 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6673612B2 (en) 1999-07-16 2004-01-06 Mirus Corporation Micellar systems
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
CA2385989A1 (en) 1999-09-27 2001-04-05 Andrew Nienstedt Compositions of tocol-soluble therapeutics
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US7842308B2 (en) 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
EP1379227A4 (en) 2001-03-21 2007-12-12 Univ Kentucky Res Found Microemulsions as precursors to solid nanoparticles
US8137699B2 (en) 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
WO2002078674A1 (en) 2001-03-30 2002-10-10 Trustees Of Princeton University A process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
ATE547095T1 (de) 2001-05-11 2012-03-15 Isis Pharmaceuticals Inc Antisense-permeationsverstärker
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
DE602004014747D1 (de) 2003-03-26 2008-08-14 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
JP3999746B2 (ja) 2003-05-19 2007-10-31 ローム アンド ハース カンパニー ポリマーナノ粒子の高固形分調製方法
GB0319451D0 (en) 2003-08-19 2003-09-17 Lonza Biologics Plc Tropolone assay
CA2558916C (en) 2003-10-20 2009-09-22 William Marsh Rice University Method to fabricate microcapsules from polymers and charged nanoparticles
CN100389766C (zh) 2003-10-30 2008-05-28 湖南省中医药研究院 二氢杨梅素在制备药物中的应用
US20050228074A1 (en) 2004-04-05 2005-10-13 Bridgestone Corporation Amphiphilic polymer micelles and use thereof
IL180785A (en) 2004-07-19 2014-03-31 Celator Pharmaceuticals Inc Preparations containing particulate structures for the release of active substances
US7651982B2 (en) 2004-08-21 2010-01-26 Halliburton Energy Services, Inc. Methods and aqueous acid solutions for acidizing wells containing sludging and emulsifying oil
US8945629B2 (en) 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
WO2006039369A1 (en) 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
US8007829B2 (en) 2005-01-19 2011-08-30 William Marsh Rice University Method to fabricate inhomogeneous particles
CA2600085A1 (en) * 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticle and pharmaceutical preparation
US20060224095A1 (en) 2005-04-05 2006-10-05 University Of New Hampshire Biocompatible polymeric vesicles self assembled from triblock copolymers
US7723438B2 (en) * 2005-04-28 2010-05-25 International Business Machines Corporation Surface-decorated polymeric amphiphile porogens for the templation of nanoporous materials
JP2006321763A (ja) * 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法
US7977024B2 (en) 2005-12-16 2011-07-12 Xerox Corporation Solvent-free toner making process using phase inversion
US20070231355A1 (en) 2006-01-23 2007-10-04 L'oreal Cosmetic composition comprising multiphasic particles
CN101848702B (zh) * 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
JP2008297288A (ja) 2007-06-04 2008-12-11 Toray Ind Inc 微粒子および製造方法
EP2185626A4 (en) 2007-08-23 2010-09-08 Medivas Llc BIODEGRADABLE POLYMERIC GENE TRANSFER COMPOSITIONS CONTAINING CATIONIC ALPHA-AMINO ACIDS
US8394914B2 (en) * 2007-08-24 2013-03-12 Board Of Trustees Of Michigan State University Functional polyglycolide nanoparticles derived from unimolecular micelles
US20090061009A1 (en) 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
US9943490B2 (en) 2007-11-05 2018-04-17 The Trustees Of Princeton University Composite flash-precipitated nanoparticles
US20110022129A1 (en) 2007-11-05 2011-01-27 Prud Homme Robert K Nanoparticles for photodynamic therapy
US8974814B2 (en) 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
US8729015B2 (en) 2007-12-21 2014-05-20 Merck Patent Gmbh Solid lipid microcapsules containing growth hormone inner core microparticles
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
WO2009121069A2 (en) 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
PE20091964A1 (es) 2008-05-06 2010-01-09 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
US20110256213A1 (en) 2008-10-15 2011-10-20 The Board Of Trustees Of The University Of Illinois Phospholipid micellar and liposomal compositions and uses thereof
JP5008009B2 (ja) 2009-02-13 2012-08-22 独立行政法人科学技術振興機構 無機−有機ハイブリッド粒子、及びその製造方法。
US20100305219A1 (en) 2009-06-02 2010-12-02 The Board Of Trustees Of The University Of Illinois Emulsions and foams using patchy particles
WO2010148653A1 (en) * 2009-06-26 2010-12-29 Shanghai Jiao Tong University Polymer vesicles of asymmetric membrane
JP5031001B2 (ja) 2009-07-02 2012-09-19 学校法人 関西大学 ナノスフェアの製造方法、ナノスフェア、これを含有する皮膚外用組成物および化粧料
EP2277557B1 (en) 2009-07-20 2014-06-25 The Procter and Gamble Company Coated superabsorbent polymer particles and processes therefore
WO2011017500A1 (en) 2009-08-06 2011-02-10 The Trustees Of The University Of Pennsylvania Amphiphilic janus-dendrimers
US8623329B1 (en) 2009-10-13 2014-01-07 Aerophase, Inc. Method for the treatment of lung tumors
US20110091560A1 (en) 2009-10-21 2011-04-21 The Burnham Institute For Medical Research Compositions of nanoparticles and methods of making the same
US9115222B2 (en) * 2009-12-29 2015-08-25 Bridgestone Corporation Well defined, highly crosslinked nanoparticles and method for making same
US20110200828A1 (en) 2010-02-16 2011-08-18 Biocoat Incorporated Hydrophilic coatings for medical devices
US8288001B1 (en) 2010-02-16 2012-10-16 Sandia Corporation Method of making monodisperse nanoparticles
US20110229516A1 (en) 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
WO2011130114A1 (en) * 2010-04-12 2011-10-20 Iowa State University Research Foundation, Inc. Nanoparticles and nanoparticle compositions
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
US8673359B2 (en) 2010-07-08 2014-03-18 Brown University Nanoparticle compositions and methods for improved oral delivery of active agents
US20120121510A1 (en) 2010-11-11 2012-05-17 Brem Rachel F Localized therapy following breast cancer surgery
CA2829629A1 (en) 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
EP2526927A1 (de) 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nano- und Mikropartikel beschichtet mit Stabilisatoren für die pulmonale Applikation
FR2976581B1 (fr) 2011-06-15 2013-07-19 Centre Nat Rech Scient Materiau auto-assemble a base de polymeres ou d'oligomeres presentant une structure lamellaire non centro-symetrique.
WO2013023003A1 (en) * 2011-08-08 2013-02-14 Rutgers, The State University Of New Jersey Bioactive amphiphilic polymer stabilized nanoparticles with enhanced stability and activity
CN102334609B (zh) 2011-08-30 2013-04-24 广州天科生物科技有限公司 二氢杨梅素金属配合物的应用
US20130064954A1 (en) 2011-09-08 2013-03-14 Maria Ochomogo Microemulsion Concentrates and Nanoemulsion Flavorant Compositions For Food Applications
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
US10076496B2 (en) 2011-11-11 2018-09-18 The Chinese University Of Hong Kong Engineering of polymer-stabilized nanoparticles for drugs with Log P values below 6 by controlled antisolvent precipitation
EP3181128B1 (en) 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Nilotinib pharmaceuticalcomposition
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US20140037573A1 (en) 2012-02-22 2014-02-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
EP3778696A1 (en) 2012-04-23 2021-02-17 NanoProteagen Ltd. Polymeric nanoparticles and a process of preparation thereof
US20140256760A1 (en) 2012-07-09 2014-09-11 Noglo Llc Reduction or prevention of alcohol reaction with dietary supplements
BR112015002055A2 (pt) 2012-08-24 2017-07-04 Dow Global Technologies Llc acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório
BR112015005878A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
EA028569B1 (ru) 2012-10-24 2017-12-29 Карджилл, Инкорпорейтед Композиция эмульгатора, содержащего фосфолипиды
MX2015004626A (es) 2012-11-29 2015-07-14 Yeda Res & Dev Metodos para prevenir metastasis de tumor, tratar y pronosticar cancer e identificar agentes que son inhibidores putativos de metastasis.
CN105188905B (zh) 2013-03-01 2019-01-15 国立研究开发法人科学技术振兴机构 物质包封微囊及其制备方法
JP6456849B2 (ja) 2013-03-01 2019-01-23 ハーキュリーズ・インコーポレーテッドHercules Incorporated 高められた性能及び改善された加工性を有する医薬組成物
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
DK3033102T4 (da) 2013-08-13 2024-02-26 Univ Northwestern Peptidkonjugerede partikler
DK3104838T3 (da) 2014-02-13 2020-02-24 Pfizer Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
WO2015130835A1 (en) 2014-02-26 2015-09-03 The Trustees Of Princeton University Polymer nanoparticles
US9603830B2 (en) 2014-05-29 2017-03-28 Thriveplus Llc Compositions and methods for preventing and recovery from detrimental effects of alcohol consumption
CN104042567A (zh) 2014-06-07 2014-09-17 福建卫生职业技术学院 一种蛇葡萄素纳米胶束及其应用
WO2015200054A2 (en) 2014-06-24 2015-12-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
EP3164420A4 (en) 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CA2965157A1 (en) 2014-11-25 2016-06-02 Nanocopoeia, Llc Method of converting a crystalline compound to an amorphous compound, method of increasing the solubility of a crystalline compound in a biorelevant fluid, and nanoparticles that achieve supersaturation
AU2016272700A1 (en) 2015-05-29 2017-12-14 Oculis ehf. Formation of cyclosporin A/cyclodextrin nanoparticles
US20170042823A1 (en) 2015-08-14 2017-02-16 The Trustees Of Princeton University Co-encapsulation of antimicrobials and adjuvants in nanocarriers
CN105213250A (zh) 2015-09-08 2016-01-06 上海应用技术学院 一种复配型天然抗菌剂及其制备方法和在化妆品中的应用
WO2017089942A1 (en) 2015-11-25 2017-06-01 Pfizer Inc. Therapeutic nanoparticles comprising an antibiotic and methods of making and using same
WO2017112828A1 (en) 2015-12-22 2017-06-29 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
EP3199148B1 (en) 2016-01-28 2020-12-02 Capsugel Belgium NV Compositions and resulting hard capsules comprising hydrophilic coloring foodstuff concentrates
WO2017168426A1 (en) 2016-03-30 2017-10-05 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
CA2972926A1 (en) 2016-07-11 2018-01-11 Mcmaster University Brush amphiphilic block copolymers, and self-assembled nanoparticles therefrom
US10357529B2 (en) 2016-11-07 2019-07-23 Rvrs, Llc Natural formulation for treating hangover
CN106750272B (zh) 2016-12-05 2019-05-28 福建卫生职业技术学院 一种水溶性蛇葡萄素聚合物
WO2019050969A1 (en) 2017-09-06 2019-03-14 Prud'homme, Robert, K. FORMULATIONS OF DIHYDROMYRICETIN NANOPARTICLES
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
JP2021501753A (ja) 2017-11-03 2021-01-21 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティThe Trustees Of Princeton University 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US20220211637A1 (en) 2019-05-09 2022-07-07 The Trustees Of Princeton University Random copolymer stabilized nanoparticles encapsulating soluble hydrophilic compounds
MX2021015457A (es) 2019-06-14 2022-04-06 Univ Princeton Formulaciones de dihidromiricetina y un permeabilizante.
WO2021046078A1 (en) 2019-09-04 2021-03-11 The Trustees Of Princeton University Comb polymer and block copolymer stabilized nanoparticles encapsulating nucleic acids and other soluble hydrophilic compounds
US11648211B2 (en) 2019-09-23 2023-05-16 Northeastern University Nanoencapsulated combination drug formulations
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine

Also Published As

Publication number Publication date
US20190151252A1 (en) 2019-05-23
EP3160449A2 (en) 2017-05-03
US12605344B2 (en) 2026-04-21
EP3160449A4 (en) 2018-02-07
US20230126007A1 (en) 2023-04-27
WO2015200054A2 (en) 2015-12-30
US10231937B2 (en) 2019-03-19
US20260216090A1 (en) 2026-07-30
JP2019163341A (ja) 2019-09-26
AU2015280417A1 (en) 2017-02-09
WO2015200054A9 (en) 2016-05-19
JP7019195B2 (ja) 2022-02-15
WO2015200054A3 (en) 2016-03-17
EP4299058A2 (en) 2024-01-03
AU2015280417B2 (en) 2020-01-30
EP4299058A3 (en) 2024-03-27
JP2017520567A (ja) 2017-07-27
US20170209386A1 (en) 2017-07-27
EP3160449B1 (en) 2023-12-13
US11554101B2 (en) 2023-01-17

Similar Documents

Publication Publication Date Title
US12605344B2 (en) Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
JP2022160693A (ja) 可溶性の生物製剤、治療薬、および造影剤を封入するためのプロセス
US11517538B2 (en) Shear-thinning self-healing networks
Elzoghby et al. Zein-based nanocarriers as potential natural alternatives for drug and gene delivery: focus on cancer therapy
Chen et al. Surface modification of mitoxantrone-loaded PLGA nanospheres with chitosan
US20230356169A1 (en) Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US12186436B2 (en) Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US20200206136A1 (en) Cellulosic polymer nanoparticles and methods of forming them
Rajan et al. Potential Drug Delivery Applications of Chitosan Based Nanomaterials.
US20220211637A1 (en) Random copolymer stabilized nanoparticles encapsulating soluble hydrophilic compounds
Guo et al. Synthesis of alginic acid− poly [2-(diethylamino) ethyl methacrylate] monodispersed nanoparticles by a polymer− monomer pair reaction system
CN1485362A (zh) 一种离子交联的壳聚糖微球及其制备方法和用途
Dmour et al. Alginate nanoparticles
Conte et al. Recent advances in “bioartificial polymeric materials” based nanovectors
Singh et al. Alginate based nanocarriers in modern therapeutics
Khan et al. Investigation of in vitro Release Dynamics of Cisplatin From Genipin Crosslinked Gelatin Nanocarriers
BG5020U1 (bg) Полимерна система с нано-в-микро архитектура за контролирано освобождаване на нискомолекулни водоразтворими лекарствени вещества
CHENGDE GELATIN-BASED BIOMATERIALS FOR DRUG AND CELL DELIVERY
DELAIR Colloidal Particles
Doddapaneni Development of Micellar and Nanoparticle Structures based on Polyester Diblock Copolymer Platform for the Treatment of Metastatic Tumors
Debnath et al. Research Paper Studies on the Preparation and Evaluation of Chitosan Nanoparticles containing Cytarabine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181206

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20181206

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20181213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190708

R150 Certificate of patent or registration of utility model

Ref document number: 6554493

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250